Cytokinetics Plans To Submit Supplemental NDA To U.S. FDA For Aficamten In Q4 2026
CYTK•Supplemental NDA filing planned for aficamten
- Cytokinetics plans to submit a supplemental NDA to the U.S. FDA for aficamten for the treatment of adult patients with symptomatic NHCM in Q4.
Further company coverage: CYTK.O
